Navigation Links
Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
Date:9/10/2007

ars of age, parents should contact their pediatrician. Maxim accepts Medicare Part B with no co-pay required, when Medicare Part B is the primary insurance.

About Maxim Health Systems

Maxim Health Systems is a division of Maxim Healthcare Services, Inc. Established in 1996, Maxim Health Systems offers a full line of comprehensive wellness services to corporate and retail clients. We provide a variety of services including immunizations, health screenings and health fairs. In 2006, our flu immunization program alone was responsible for vaccinating more than 3.7 million people. Together with Maxim Healthcare Services, we have branch locations in most metropolitan areas across the nation. For more information contact us at: http://www.FindaFluShot.com/contact.php.


'/>"/>
SOURCE Maxim Health Systems
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. The Link Between Childhood Vaccinations And Diabetes Questioned
2. Myth Of Childhood Vaccinations Linked To Increased Hospitalization Busted
3. Media Plays Crucial Role In Flu Vaccinations
4. Tourists Face Health Risks by Missing Vaccinations
5. Risk of heart disease begins in teens
6. Experts Recommend Preventive Measures For Avian Flu To Begin From Farms
7. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
8. Cancer Begins With Epigenetic Changes: Study
9. Learning About Healthy Diet Choices Begins At Schools
10. China Begins Human Trials For HIV/AIDS Drug
11. Pilot Study to Test Effect of Mobile Phone Transmissions On Skin To Begin In Finland
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Treatment Programs Benefit Depressed Workers 2Health News:Treatment Programs Benefit Depressed Workers 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 2Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 4Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 2Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 3Health News:AHF Launches 'Public Health Division' 2Health News:AHF Launches 'Public Health Division' 3Health News:AHF Launches 'Public Health Division' 4Health News:'Making the Case:' special double issue of Critical Inquiry 2Health News:'Making the Case:' special double issue of Critical Inquiry 3Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 2Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 3
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 656 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 156 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 256 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3Pelosi and Reid Invite President Obama to Address Congress 56085 1Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2